First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

NCT05759949 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

PIK3CA Mutation
Solid Tumor, Adult
HER2-negative Breast Cancer
Breast Cancer
Metastatic Breast Cancer
Advanced Breast Cancer
Unresectable Solid Tumor
Hormone Receptor Positive Tumor

Interventions

DRUG: RLY-5836
DRUG: Fulvestrant
DRUG: Palbociclib
DRUG: Ribociclib
DRUG: Abemaciclib

Sponsor

Relay Therapeutics, Inc.